Drug Profile
Recombinant alpha-antitrypsin - Alteogen
Alternative Names: Recombinant A1AT - AlteogenLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Alteogen
- Developer Alteogen; Lynkogen
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antihyperglycaemics; Blood proteins; Recombinant fusion proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Alpha 1-antitrypsin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Emphysema; Metabolic disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Metabolic-disorders in South Korea
- 28 Sep 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in South Korea
- 28 Jan 2020 No recent reports of development identified for preclinical development in Emphysema in South Korea